


## EGFR-IN-70

Cat. No.:	HY-150611		
CAS No.:	2926716-96-1		
Molecular Formula:	C <sub>31</sub> H <sub>36</sub> ClN <sub>5</sub> O <sub>5</sub> S		
Molecular Weight:	626.17		
Target:	EGFR		
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : 100 mg/mL (159.70 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.5970 mL	7.9851 mL	15.9701 mL
5 mM	0.3194 mL	1.5970 mL	3.1940 mL
10 mM	0.1597 mL	0.7985 mL	1.5970 mL

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

### Description

EGFR-IN-70 (compound 18j) is a potent EGFR inhibitor with IC<sub>50</sub> values of 23.6 and 307.5 nM for EGFR<sup>LR/TM/CS</sup> and EGFR<sup>WT</sup>, respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR. EGFR-IN-70 can be used for cancer research<sup>[1]</sup>.

### IC<sub>50</sub> & Target

IC<sub>50</sub>: 23.6 nM (EGFR<sup>LR/TM/CS</sup>) and 307.5 nM EGFR<sup>WT</sup><sup>[1]</sup>

### In Vitro

EGFR-IN-70 (compound 18j) (72 hours) has anti-proliferative activity and suppresses the proliferation of Ba/F3-EGFR<sup>19del/TM/CS</sup>, PC-9-OR-EGFR<sup>19del/TM/CS</sup> and A431-EGFR<sup>WT</sup> cells with IC<sub>50</sub> values of 0.052, 0.644 and 2.003 μM, respectively<sup>[1]</sup>. EGFR-IN-70 (compound 18j) (0-1000 nM; 2 hours; Ba/F3-EGFR<sup>19del/TM/CS</sup> and PC-9-OR-EGFR<sup>19del/TM/CS</sup> cells) can suppress phosphorylation of the EGFR<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line: Ba/F3-EGFR<sup>19del/TM/CS</sup> and PC-9-OR-EGFR<sup>19del/TM/CS</sup> cells

Concentration: 1, 3, 10, 30, 100, 300 and 1000 nM

---

Incubation Time:	2 hours
Result:	Suppressed phosphorylation of the EGFR and the downstream signaling ERK level.

---

## REFERENCES

---

[1]. Chen H, et, al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA